公开(公告)号：US08318491B2

公开(公告)日：2012-11-27

申请号：US12671814

申请日：2007-10-02

申请人： Inpyo Choi ,  SukRan Yoon ,  Sohyun Yun ,  Jin Woong Chung

发明人： Inpyo Choi ,  SukRan Yoon ,  Sohyun Yun ,  Jin Woong Chung

IPC分类号： C07K5/02 ,  C12N5/02 ,  C07D209/04

CPC分类号： A61K31/416

摘要： The present invention relates to an agent for differentiating hematopoietic stem cells into natural killer cells and a method for the differentiation, more precisely an agent for differentiating hematopoietic stem cells into natural killer cells comprising YC-I [3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole] or IL-21 (Interleukin-21) as an active ingredient and a method for differentiating hematopoietic stem cells into natural killer cells using the same. The YC-I and IL-21 regulate the differentiation of hematopoietic stem cells into natural killer cells and increase the killing activity of NK cells. Therefore, the agent for NK cell differentiation of the present invention can be effectively used for cell therapy for the treatment of cancer by regulating the differentiation of hematopoietic stem cells into natural killer cells having tumor cell killing activity.

摘要翻译： 本发明涉及用于将造血干细胞分化为天然杀伤细胞的试剂和分化方法，更准确地说，用于将造血干细胞分化成包含YC-1 [3-（5'-羟甲基-2 糠基）-1-苄基吲唑]或IL-21（白细胞介素-21）作为活性成分，以及使用其将造血干细胞分化为天然杀伤细胞的方法。 YC-1和IL-21调节造血干细胞分化为自然杀伤细胞，增加NK细胞的杀伤活性。 因此，通过调节造血干细胞分化为具有肿瘤细胞杀伤活性的天然杀伤细胞，本发明的NK细胞分化剂可以有效地用于治疗癌症的细胞治疗。

公开(公告)号：US20110033415A1

公开(公告)日：2011-02-10

申请号：US12671814

申请日：2007-10-02

申请人： Inpyo Choi ,  SukRan Yoon ,  Sohyun Yun ,  Jin Woong Chung

发明人： Inpyo Choi ,  SukRan Yoon ,  Sohyun Yun ,  Jin Woong Chung

IPC分类号： A61K38/20 ,  C12N5/0783 ,  A61K35/12 ,  A61P35/00

CPC分类号： A61K31/416

摘要： The present invention relates to an agent for differentiating hematopoietic stem cells into natural killer cells and a method for the differentiation, more precisely an agent for differentiating hematopoietic stem cells into natural killer cells comprising YC-I [3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole] or IL-21 (Interleukin-21) as an active ingredient and a method for differentiating hematopoietic stem cells into natural killer cells using the same. The YC-I and IL-21 regulate the differentiation of hematopoietic stem cells into natural killer cells and increase the killing activity of NK cells. Therefore, the agent for NK cell differentiation of the present invention can be effectively used for cell therapy for the treatment of cancer by regulating the differentiation of hematopoietic stem cells into natural killer cells having tumor cell killing activity.

摘要翻译： 本发明涉及用于将造血干细胞分化为天然杀伤细胞的试剂和分化方法，更准确地说，用于将造血干细胞分化成包含YC-1 [3-（5'-羟甲基-2 糠基）-1-苄基吲唑]或IL-21（白细胞介素-21）作为活性成分，以及使用其将造血干细胞分化为天然杀伤细胞的方法。 YC-1和IL-21调节造血干细胞分化为自然杀伤细胞，增加NK细胞的杀伤活性。 因此，通过调节造血干细胞分化为具有肿瘤细胞杀伤活性的天然杀伤细胞，本发明的NK细胞分化剂可以有效地用于治疗癌症的细胞治疗。